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Increased or reduced action of thyroid hormone on certain molecular pathways in the heart and vasculature causes relevant
cardiovascular derangements. It is well established that hyperthyroidism induces a hyperdynamic cardiovascular state, which is
associatedwithafasterheartrate,enhancedleftventricularsystolicanddiastolicfunctionwhereashypothyroidismischaracterized
by the opposite changes. Hyperthyroidism and hypothyroidism represent opposite clinical conditions, albeit not mirror images.
Recent experimental and clinical studies have suggested the involvement of ROS tissue damage under altered thyroid status.
Altered-thyroid state-linked changes in heart modify their susceptibility to oxidants and the extent of the oxidative damage they
suﬀer following oxidative challenge. Chronic increase in the cellular levels of ROS can lead to a catastrophic cycle of DNA damage,
mitochondrial dysfunction, further ROS generation and cellular injury. Thus, these cellular events might play an important role
in the development and progression of myocardial remodeling and heart failure in altered thyroid states (hypo- and hyper-
thyroidism). The present review aims at elucidating the various signaling pathways mediated via ROS and their modulation under
altered thyroid state and the possibility of antioxidant therapy.
1.Introduction
Heart failure is one of the leading causes of mortality all over
the world. Heart failure (HF) is a ﬁnal common pathway
of various cardiovascular diseases, including sustained pres-
sure overload (i.e., hypertension), myocardial ischemia or
infarction, volume overload (i.e., valvular heart disease), and
inherited or acquired cardiomyopathies. The mechanisms
responsible for the progression of heart failure are emerging,
and thyroid hormone-induced oxidative damage is one of
them. Heart is one of the main target organs for the action
of thyroid hormone, and any change in the thyroid hormone
status indirectly aﬀects the cardiac function [1]. Growing
evidences have suggested that while hypermetabolic state in
hyperthyroidism is associated with increase in free radical
production [2, 3], the hypometabolic state induced by
hypothyroidismleadstoadecreaseinfreeradicalproduction
[4].
Mammalianheartbeinganobligateaerobicorgancannot
produce enough energy under aerobic conditions to main-
tain cellular metabolism. Thus, a constant supply of oxygen
is needed to sustain cardiac functions. Oxygen acts as the
terminal electron acceptor in electron transport chain and
in the absence of suﬃcient oxygen, electron transport ceases,
and cardiac energy demand is not met. However, oxygen
apart from its life sustaining role also takes part in the
mechanisms leading to oxidative stress. Oxidative stress is
deﬁned as the imbalance between the generation of reactive
oxygen species (ROS) as a consequence of incomplete
reduction of oxygen and antioxidant defense system. ROS
can be induced in the heart by a variety of mechanisms such
as xanthine oxidase, NAD(P)H oxidase, cytochrome P450
(CYP450), autoxidation of catecholamines and uncoupling
of NO synthase (NOS), or by mitochondrial leakage. ROS
formation in the heart can be induced by the action of
cytokines and growth factors as well. Angiotensin II, PDGF,
and TNF-α, for example, can induce hydrogen peroxide
(H2O2) and superoxide radical (O2
•−) formation via activa-
tion of the NAD(P)H oxidase [5]. Thus, the major processes
from which heart derives suﬃcient energy can also result in
the production of ROS.2 The Scientiﬁc World Journal
2. Reactive Oxygen Species and
TheirMetabolism
ROS are highly reactive molecules that include free radicals,
such as O2
•− and hydroxyl (
•OH), which have one or
more unpaired electrons, as well as compounds such as
H2O2 that are not free radicals. O2
•− is produced by single-
electron reduction of molecular oxygen, and it undergoes
dismutation by superoxide dismutase (SOD) (EC 1.15.1.1)
to generate H2O2 which is usually broken down by catalase
(EC 1.11.1.6) or glutathione peroxidase (EC 1.11.1.9) to
H2O. The single-electron reduction of H2O2 results in the
formation of highly reactive and potent hydroxyl radical
(
•OH), via the Fenton or the metal catalysed Haber-weiss
reactions. Superoxide may react with local NO
• to generate
peroxy nitrite (ONOO
•) which is itself a potent ROS. The
actions of most ROS conﬁned to the intracellular com-
partment of production because of their limited diﬀusion
capacity.Incontrast,H2O2 candiﬀuseacrosscellmembranes
and therefore has the potential to act at more distant sites
[5].
Small intracellular antioxidants such as vitamin E and C,
β-carotene, ubiquinone, lipoic acid, urate, and glutathione
are categorized under nonenzymatic pathways. Glutathione
also acts as reducing substrates for enzymatic activities
of glutathione peroxidase. Thioredoxin and thioredoxin
reductase catalyses the regeneration of a number of antiox-
idant molecules [6] including ubiquinone, lipoic acid, and
ascorbic acid, and their absence results in developmental
heart abnormalities and in cardiac death secondary to a
severe dialated cardiomyopathy [7].
3.Biological SigniﬁcanceofROS
ROS serve an important role in several important biological
processes. At physiological concentrations ROS can function
as secondary messengers downstream of speciﬁc ligands
including TGF-β1, PDGF, ATII, FGF2, endothelin, and
others [8–11]. ROS also modulates the activity of speciﬁc
transcription factors like NF-κB and activator protein-1
(AP1) [12–15]. They also have a role in modulating inﬂam-
mation and play an essential role in normal cell proliferation
and growth. In addition they stimulate DNA synthesis and
induce the expression of growth-related genes including c-
fos, c-jun, and c-myc [16].
Under pathophysiological conditions, dramatically ele-
vated levels of ROS may cause signiﬁcant damage to cellular
proteins and membranes as well as to nucleic acids. They
cause damage to cell membrane and membranes of cellular
organelles by causing peroxidation of membrane lipids [17,
18]. Modiﬁcation of proteins by ROS leads to inactivation
and denaturation of critical enzymes [19, 20]. Introduction
of strand breaks in DNA by ROS leads to mutagenesis and,
thus, signiﬁcantly aﬀects gene expression [21, 22]. General
ageing and age-related alterations in the cardiovascular
systems have been attributed to the long-term cumulative
eﬀect of ROS [23, 24]. A number of evidences suggest the
role of thyroid hormone in the generation of ROS due to its
eﬀect on the general metabolism of body.
4. Thyroid Hormone-Induced OxidativeStress
Thyroid hormone (3,3 ,5-triiodothyronine, T3)e x e r t ss i g -
niﬁcant actions on energy metabolism, with mitochondria
being the major target for its calorigenic eﬀects. Acceleration
of O2 consumption by T3 leads to an enhanced generation
of ROS and reactive nitrogen species (RNS) in target tissues,
with a higher consumption of cellular antioxidants and
inactivation of antioxidant enzymes, thus inducing oxidative
stress. A primary intracellular target for oxidative stress-
induced tissue damage due to the TH is the mitochondria,
thepowerhouses forcellularlife.Within heartmitochondria,
the major locus for O2
•− production is complex III in both
euthyroid and hypothyroid states [25, 26]. Increase number
of evidences point out that overall antioxidant capacity
of mitochondria decreases in hyperthyroid heart, and this
increases the susceptibility of mitochondria to oxidants
(Figure 3).
5. Mechanismof Thyroid Hormone
Action on Heart
TH induces changes in cardiac parameters by acting on some
molecular pathways in the heart. The mode of action may
be direct eﬀect on transcription on speciﬁc and nonspeciﬁc
cardiac genes (genomic eﬀect) [27], and the other mode of
action is on the action on plasma membrane, mitochondria,
and sarcoplasmic reticulum (nongenomic) [28]. T3 and T4
because of their lipophilic nature can easily diﬀuse across
the cytoplasmic membrane of cardiomyocytes. There is
no evidence of conversion of T4 to T3 in cardiomyocytes
[29]. Lipophilic T3 enters the nucleus where it binds to
inactive thyroid hormone receptors (THRs) thus convert-
ing it to activated form that either homodimerizes or
heterodimerizes with 9-cis-retinoic acid receptor, and the
complex thus formed recognizes one of the several DNA
consensus sequences and the thyroid response elements
(TRE), located in the enhancer region of target genes [30,
31].Thebindingofproteincomplextotheresponseelements
activates the promoter of the target gene resulting in the
initiation of transcription. There are a number of cardiac
genes recognized as targets for transcriptional activation
by thyroid hormone which include myosin heavy chain
α (MHC-α), SERCA, Na-K-ATPase, β-adrenergic receptor,
cardiactroponinI,andatrialnatriureticpeptide[32–37].On
the other hand transcription of some other gene like myosin
heavy chain β (MHC-β) is repressed [38]. In this regard,
several lines of evidence suggest that the altered thyroid
status in patients with cardiovascular disorders could modify
cardiac gene expression and contribute to impaired cardiac
function (Figure 1).
6.Heart Failureand
the Role of ThyroidHormone
With age heart loses some blood-pumping ability, but
heart failure (HF) results from the added stress of health
conditions that either damage the heart or make it work
too hard. A single risk factor may be suﬃcient to causeThe Scientiﬁc World Journal 3
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Figure 1: Eﬀects of thyroid hormone on cardiac function.
HF, but a combination of factors dramatically increases the
risk. Heart failure itself is not a disease, but, rather, it is
a syndrome that develops as the result of many conditions
that damage the heart. Patients who have more than one
condition face an even greater risk of developing heart
failure. These conditions include (i) coronary artery dis-
ease (artherosclerosis, myocardial infarction, and ventricular
remodelling), (ii) heart muscle disease (dilated cardiomy-
opathy, hypertrophic cardiomyopathy or inﬂammation or
myocarditis), (iii) abnormal heart valves, (iv) heart defects
present at birth (congenital heart disease) and (v) high blood
pressure (hypertension) (Figure 1).
6.1. Coronary Artery Disease. The heart is a muscle that
w o r k s2 4h o u r sad a y .T op e r f o r mw e l l ,i tn e e d sac o n s t a n t
supply of oxygen and nutrients, which is delivered by the
blood through the coronary arteries. Coronary artery disease
is the disease of the artery associated with accumulation
of arethromatous plaque within the wall of the arteries
that supply blood to the myocardium. Several risk factors
for coronary heart disease have been well documented,
including hypertension, hyperlipidemia, diabetes, a positive
family story, smoking, obesity, and inactivity. However,
these factors explain only in part to be attributable for
cardiovascular disease. Evidence suggests that ROS may play
an important role in the pathogenesis of coronary artery
disease [5]. Coronary artery disease can lead to a heart attack
(or myocardial infarction), which causes permanent damage
to the heart muscle. In some cases, when there is a larger
amount of damage, this can lead to HF.
6.1.1. Atherosclerosis. Coronary atherosclerosis is the leading
cause of death worldwide, accounting for 1/3rd of total death
in industrialized countries. Atherosclerosis is a complex
process involving the deposition of plasma lipoproteins and
the proliferation of cellular elements in the artery wall. This
chronicinﬂammatoryconditionadvancesthroughaseriesof
stages beginning with fatty streak lesions composed largely
of lipid-engorged monocyte-derived macrophage foam cells
and ultimately progressing to complex plaques consisting
of a core of lipid and necrotic cell debris covered by a
ﬁbrous cap. These plaques provide a barrier to arterial
bloodﬂowandmayprecipitateinclinicalevents,particularly
under conditions that favor plaque rupture and thrombus
formation [5].
Oxidative stress modulates many pathological events
crucial in the onset and progression of vascular disease such
as oxidation of LDL, reduction of NO bioavailability, and
vascular inﬂammation. As the process of atherogenesis pro-
ceeds, large amounts of ROS are released by inﬂammatory
cells, as well as other constituents of atherosclerotic plaque
which further facilitates atherogenesis. ROS may aﬀect
more than one fundamental mechanisms that attribute to
atherogenesis like oxidation of lipids, endothelium dysfunc-
tion, proliferation of vascular smooth muscle cells (SMCs),
increased adhesion of monocytes to endothelial cells, and
hyperlipidemia [39].
Oxidatively modiﬁed LDL (Ox-LDL) is a more potent
proatherosclorotic mediator [40]. It causes the alteration
of endothelial cells lining the arterial wall, resulting in
expression of several monocytes/macrophages, which in
turn release a number of growth factors [41–43]. Ox-LDL
facilitates formation of matrix metalloproteins (MMPs) in
vascular endothelial cells and ﬁbroblasts. It also upregulates
the expression of endothelial receptors which is responsible
for the formation of foam cells, which is an early step in4 The Scientiﬁc World Journal
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Figure 2: Potential sources of reactive oxygen species (ROS) and their eﬀects on cardiac function. Cytp450: cytochrome p450, NOS: nitric
oxide synthase, PDGF: platelet-derived growth factor, TNF-α: tumor necrosis factor, ASK-I: apoptosis-regulating signal kinase, MAPK:
mitogen-activated protein kinases, NFκB: nuclear factor κB, MMP: matrix metalloproteinase, AngII: Angiotension II, ATIR: Angiotension I
receptor, and SERCA: sarcoplasmic endoplasmin reticulum calcium ATPase.
atherogenesis. Ox-LDL induces apoptosis in human coro-
nary artery endothelial cells by increasing ROS production
(Figure 2)[ 41].
Endothelial dysfunction is an important early prognostic
marker in the pathogenesis of atherosclerosis, contributing
to plaque initiation and progression and is characterized
by impaired endothelium-dependent vasodilation [44]. In
addition to the above important characteristic feature of
endothelial dysfunction, there is impaired synthesis, release,
and activity of endothelium-derived NO which when inacti-
vated by superoxide anion restricts its availability and results
in nitrate tolerance, vasoconstriction, and hypertension as
well as atherosclerosis (Figure 2)[ 45].
ROS can induce vascular smooth muscle cell (SMC)
growth and proliferation which is a characteristic feature of
atherosclerosis. ROS increases SMC growth by stimulation
of the expression of ﬁbroblast growth factor (FGF) and
ﬁbroblast growth factor receptor-1 (FGFR-1), insulin-like
growth factor-1 (IGF-1), and insulin like growth factor-
1r e c e p t o r( I G F - 1 R )a sw e l la se p i d e r m a lg r o w t hf a c t o r
receptor(EGFR)[46–49].EvidencessuggestROSgeneration,
via NADPH oxidase activation, plays a critical role in Ang
II-induced vascular SMC proliferation, and hypertrophy in
[50]. Large amount of ROS is required to induce vascular
SMC death by either apoptosis or necrosis; however, this
process occurs in the ﬁnal stage of atherosclerosis (Figure 2)
[51].
The progression and development of atherosclerosis in
humans is linked to increased adhesion of monocytes to
endothelial cells. A number of studies have shown ROS
upregulates the expression of various molecules in the
vascular endothelium which are signiﬁcant in the adhesion
of monocytes to endothelial cells like that of intercellular
adhesion molecule-1 (ICAM-1) [52], monocyte chemo-
attractant protein-1 (MCP-1) [53], platelet endothelial cell
adhesionmolecule-1(PECAM-1),andvascularcelladhesion
molecule-1 (VCAM-1) (Figure 2)[ 52, 54].
Hyperlipidemia is a major inducer of oxidative stress and
plays a very important role in atherogenesis in susceptible
animals and humans [55–57]. In hyperlipidemic patients,
there is presence of abnormally high levels of LDL particles
due to the enrichment of triglycerides and the high apo-B
cholesterol [58]. It has been recently conﬁrmed that ox-LDL
induces proatherosclerotic NADPH oxidase expression and
superoxide anion formation in human vascular endothelial
cells [59], and this may be one mechanism by which ox-
LDL stimulates ROS generation resulting in endothelial
dysfunction as well as atherosclerosis (Figure 2).
Hyperthyroidism and hypothyroidism represents oppo-
site clinical conditions, albeit not mirror images. Hyperthy-
roidism is characterized by enhanced oxidative metabolism
and markedly reduced lipid and lipoprotein plasma levels. In
the hypermetabolic state characterized by hyperthyroidism,
there is acceleration of free radical production, LPx in the
mitochondria,andchangesintheantioxidantdefensesystem
[3, 59]. Arachidonic acid content which is a polysaturated
fatty acid increases in hyperthyroidism and contributed to
increase in LPx. On the other hand, hypothyroidism is char-
acterized by reduced oxidative metabolism and markedly
increased lipid and lipoprotein plasma levels because ofThe Scientiﬁc World Journal 5
metabolic suppression caused due to lower TH [4, 60, 61].
Hypothyroid patients also show higher LPx than normo-
cholesterolemic subjects which are characterized by a sig-
niﬁcant higher LDL content in the lipid peroxides and
higher oxidation rate. In comparison to normal subjects,
there was signiﬁcant reduction in the Vitamin E content
and elevation of β-carotene levels, which can be accounted
by a blockage of β-carotene conversion to Vitamin E due
to lack of TH [62]. As a result of this possible prooxidant
activity due to elevated β-carotene LDL content and lack
of eﬀective antioxidant protection, the higher than normal
LDLoxidationinhypothyroidpatientscanbeexplained[63].
Hypothyroid patients also suﬀer from hypercholestemia
which is due to decreased fractional clearance of LDL by a
reduced number of LDL receptors in addition to decreased
receptor activity [64]. There is evidence of lowering oleic to
linoleicacidratiowhichisinverselyproportionaltooxidative
stress in both the altered thyroid states and could account for
the high oxidation rates (Figure 2)[ 65].
6.1.2. Myocardial Infarction. Myocardial infarction is one
of the major conditions associated with coronary artery
disease. MI occurs when blood supply to part of heart is
interrupted due to occlusion of a coronary artery by throm-
bosis following the rupture of a vulnerable atherosclerotic
plaque, which is an unstable collection of lipids and white
blood cells (especially macrophages) in the wall of an artery
[39]. The resulting ischemia and oxygen shortage, if left
untreated for a suﬃcient time, can cause damage and/or
death (infarction) to myocardium. Myocardial infarction
results in the migration of macrophages, monocytes, and
neutrophils into the infarct zone which in turn generates an
inﬂammatory response by initiating intracellular signaling
and neurohormonal activation. Inﬂammatory response is
associated with increased generation of ROS which in turn
contributes to the formation of ox-LDL leading to the
development of atherosclerotic plaque and augmentation of
MMPs leading to vessel plaque rupture, coronary thrombo-
sis, and occlusion (Figure 2)[ 5].
MI is usually initiated by myocardial ischemia as a result
of narrowing of arteries during artherosclerosis and ROS
are generated, after reperfusion. Myocardial ischemia is sug-
gestedtoaﬀectcontractilityofmyocardiumasaconsequence
of cell death by either necrosis or apoptosis. However, if the
coronary ﬂow is not restored within a critical period of time,
reperfusion itself may cause a wide variety of harmful eﬀects
in the ischemic heart a phenomenon referred to as “‘reper-
fusion injury”’ [66–71]. Ischemic injury is associated with
alterations in myocardial metabolism, including depletion
of energy stores while reperfusion injury is associated with
additional changes, including the development of oxidative
stress and the occurrence of intracellular Ca2+ overload.
The initial process contributing to ischemic injury is a
reductionofcellularenergystatusasaresultofcompromised
mitochondrial production of ATP via impaired oxidative
phosphorylation and electron transport due to reduced
deliveryofoxygenandsubstratestothemyocardium.Inspite
of the increase in anaerobic glycolysis in ischemic hearts, this
metabolic change is not suﬃcient to meet the high-energy
demands for maintaining cardiac function [66, 70, 72].
Mitochondrial electron transport system derangement also
promotes the generation of oxyradicals and development of
oxidative stress in the ischemic heart [68, 73]. Myocardial
ischaemia either with or without reperfusion induces ROS
and inﬂammatory cytokines. Inﬂammatory cytokines, for
example, tumour necrosis factor-α (TNF-α), IL-1b, and IL-6
are produced as a host reaction in the ischaemic region and
surrounding myocardium, and this activate is the MMPs and
collagen deposit which contribute to the structural changes
and tissue repair of injured myocardium [74].
Ischemia reperfusion has been considered model of oxi-
dative injury to test the view of reduced capability of hyper-
thyroid tissues to face oxidative damage. It has been found
that during reperfusion following 20 minutes ischemia,
hyperthyroid hearts displayed signiﬁcant tachycardia which
results in decline in antioxidant capacity and is associated
with the reduced capacity of the hyperthyroid heart to face
an oxidative stress [75]. There are instances of wider range
of oxidative damage to lipids and proteins parallel to a
higher rate of H2O2 production due to ischemicreperfusion
in mitochondria from hyperthyroid hearts than in those
from euthyroid hearts (Figure 2). In addition the concen-
tration of important liposoluble antioxidants like ubiquinols
and Vitamin E signiﬁcantly reduces after an episode of
ischemiareperfusion in hyperthyroid hearts which could
lead to increase in the extent of mitochondrial dysfunction
and tissue impairment following damaging action of nitric
oxide. The decline in mitochondrial respiration could also
be due to combination of oxidative stress and the increase
in Ca2+ concentration that occurs in myocardial cells during
ischemiareperfusion [75]. In presence of Ca2+ oxidative
alternationsofmitochondrialinnermembraneproteinthiols
leading to mitochondrial permeability transition (MPT) that
leads to mitochondrial swelling [76].
Calcium ions are essential for cardiac contractions and
relaxation. ROS act as cardiodepressant through impairment
of Ca2+ homeostasis through direct eﬀects on membrane
proteins involved in the regulation of cation transport and
LPX,whichcausesachangeinmembranepermeability.They
cause intracellular Ca2+ ion inﬂux mediated by increased
membrane LPX and opening of voltage-sensitive Ca2+
channels or Na+/Ca2+ exchanger leading to accumulation of
intracellular Na and Ca ions (Figure 2)[ 77, 78]. Speciﬁcally,
ischemia reduces the activity of sarcolemmal Na/K-ATPase,
increasestheactivityoftheNa+-H+ exchanger,andpromotes
the activation of the Na+-Ca2+ exchanger in a reverse mode.
Calcium transport is also aﬀected by ischemiareperfusion
because oxidative stress adversely inﬂuences Ca2+ handling
proteins in the sarcoplasmic reticulum (Ca2+ pump, sar-
coplasmic reticulum Ca2+-ATPase, and the Ca2+ release
channel) and sarcolemma (sarcolemmal Ca2+,pump and
the L-type Ca2+ channels) and thus contributes to the
development of an intracellular Ca2+ overload [71, 79]. The
pathological eﬀects induced by intracellular Ca2+ overload
are mediated by Ca2+-induced activation of membrane
phospholipases and proteases. ROS depress the activity of
sarcoplasmic reticulum Ca2+ ATPase (SERCA2) a membrane6 The Scientiﬁc World Journal
calciumpump,whichplaysacrucialroleincalciumhandling
and a determinant of myocardial contractility [80].
Thyroid hormone regulates expression of speciﬁc cardio-
myocyte genes independent of its eﬀects on cardiac growth
and protein synthesis. Thyroid hormone critically regulates
cardiac performance since several genes encoding important
structural and regulatory proteins in the myocardium,
including myosin isoform expression, calcium-cycling pro-
teins, and protein kinases (such as PKCα and PKCε known to
phosphorylate cardiac contractile proteins) are thyroid hor-
mone responsive. Certain T3-responsive cardiac genes, the
myosin heavy chains (MHC), phospholamban (PLB), and
sarcoplasmic reticulum calcium-activated ATPase (SERCA2)
are important determinants of cardiac contractility [81].
T h ep e r f o r m a n c eo fS E R C Ai si n ﬂ u e n c e db yt h el e v e lo f
expression of phospholamban which is inversely propor-
tional to SERCA activity. Low expression of phospholamban
and higher expression of SERCA are responsible for calcium
uptake into lumen of sarcoplasmic reticulum and thus regu-
late myocardial relaxation during diastole. It has been found
thatTHupregulatesexpressionofSERCAanddownregulates
expression of phospholamban, thereby enhancing myocar-
dial relaxation [82]. Thyroid hormone not only promotes
the phosphorylation of phospholamban, on SERCA but also
eﬀects the expression of other ion channels such as Na+/K+-
activated ATPases, Na+/Ca2+ exchanger and some voltage-
gated K+ channels, thereby coordinating the electrochemical
and mechanical responses of the myocardium [83, 84]. Low
T3 state after acute MI may contribute to the changes in
cardiac speciﬁc gene expression and further compromise
the cardiac myocyte in its response to the ischemic injury.
In hypothyroidism, there is signiﬁcant increase in PLB
content and decrease in SERCA level in the heart resulting
i nd e c r e a s e dS RC a 2+ uptake parameters [85, 86]. Treat-
ment with T3-promoted phosphorylation of PLB, thereby
decreasing its inhibitory action on sarcoplasmic reticulum
calcium uptake and improving LV function. Therefore, it is
plausible that, as a result of the low serum T3 after acute MI,
cardiac PLB was similarly altered and that T3 replacement
improvedmyocytecontractilitythroughthispathway.Onthe
other hand, hyperthyroidism results in increase in SERCA
and decrease in PLB levels results in higher number of SR
Ca2+ pumps leading to increased uptake of SR Ca2+ and
thus hasten cardiac relaxation as compared to euthyroid
hearts [87]. Thus, hypothyroid and hyperthyroid hearts are
associated inversely with each other in the levels of SERCA,
and PLB to the alterations in contractile parameters.
6.1.3. Ventricular Remodeling. Myocardial infarction (MI)
is followed by a very important structural event that is
left ventricular (LV) remodeling. MI results in acute loss
of myocardium and is frequently followed over weeks and
months by a series of alterations in cardiac structure, func-
tion, geometry, and volume collectively known as cardiac
remodeling [88, 89]. Cardiac remodeling plays an important
role in the progression of cardiovascular diseases including
myocardial infarction, valvular heart diseases, myocarditis,
and dilated cardiomyopathy. In addition to cardiac myo-
cytes, ﬁbroblasts, extracellular matrix proteins, and coronary
vasculature are also involved in the remodeling process. Car-
diac remodeling is associated with alterations of many medi-
ators such as neurohumoral factors, cytokines, enzymes, ion
channels, oxidative stress, and mechanical stress. Although
remodeling is initially an adaptive response to maintain
normal cardiac function, it gradually becomes maladaptive
and leads to progressive decompensation. Growing evidence
suggest that ROS are involved in the pathophysiology of
myocardial remodeling and failure. The mechanism involved
in left ventricular (LV) remodelling is multifactorial and
involves many biological processes which are related to
each other like ischaemia, oxidative stress, inﬂammatory
cytokines, activations of matrix metalloproteinases (MMPs),
mechanical stress, hypertrophy, and apoptosis/necrosis. Left
ventricular (LV) remodeling ultimately elicits LV dilatation
accompanied by LV dysfunction and thus could be one of
the most important causes of MI [88, 89]. The following
paragraph summarizes the recent data on the events and
pathways during ventricular remodeling with special refer-
ence to oxidative stress.
ROS has also a role in the process underlying cardiac
remodeling by modulating extracellular matrix function via
eﬀects on ﬁbroblast proliferation and collagen synthesis,
which may in turn activate MMPs, levels of which are
increased following MI. Sustained MMP activation might
inﬂuence the structural properties of the myocardium
by providing an abnormal extracellular environment with
which the myocytes interact, leading to development of
left ventricular remodeling and failure. After MI, MMPs,
and tissue inhibitors of MMPs (TIMPs) have a major
contribution in cardiac repair and LV remodelling. MMPs
constitute a family of endopeptidases having zinc at their
active site, dependency on Ca2+ for their activity, and an
abilitytoreactwithspeciﬁctissueinhibitors(TIMPs)toform
enzymatically inactive complexes [90]. A balance between
MMP and TIMP activities is a prerequisite for normal
function of an array of physiologic processes, and disruption
of this balance may result in diseases associated with
uncontrolled turnover of extracellular matrix (ECM). It is
also reported that inﬂammatory cytokines and ROS mediate
MMP induction or stimulation and decrease TIMP levels
andcollagensynthesis[91].Structuralchangesofmyocardial
tissue are elaborated by sustained induction of inﬂammatory
cytokines. The triple-helical structure of collagen renders
it resistant to proteolytic degradation, except by MMPs,
which are secreted into the extracellular matrix in their
latent proenzyme form. Collagenolytic activity is conﬁned
to regions of injury by TIMPs. These low-molecular-weight
proteins form high-aﬃnity complexes with activated MMPs
and neutralize collagen degradation by blocking the catalytic
domain of MMPs. The synthesis of TIMPs is modulated by
the levels of activated MMPs, such that collagen degrada-
tion reﬂects the disequilibrium between MMPs and TIMPs
(Figure 2)[ 92].
It is now recognized that cardiac dysfunction after acute
myocardial infarction (AMI) is due to the extent of remod-
eling of viable myocardium. Thyroid hormone signaling
probably plays an important role in pathophysiology of
cardiacremodelingatlaterstagesaftermyocardialinfarction.The Scientiﬁc World Journal 7
However, thyroid hormone administration shortly after left
coronary ligation displayed striking eﬀects on cardiac
remodeling and consequently on cardiac function. In fact, in
viable myocardium, the expression of α-MHC and the ratio
of SERCA/PLB were increased while ß-MHC expression, was
decreased [93]. Furthermore, PKCα expression was signiﬁ-
cantly reduced while PKCε expression further declined, both
of which are regulated by thyroid hormone [94]. During this
process, a fetal-like phenotype is recapitulated including a
shift to fetal pattern of myosin isoform expression with an
increase in β-MHC and decrease in α-MHC expression and
TH is a major contributor to this process by changing the
thyroid hormone-thyroid hormone nuclear receptors axis
[93, 95, 96]. Cardiac performance is critically regulated by
thyroid hormone because several genes encoding important
structural and regulatory proteins in the myocardium, like
myosin isoform expression, calcium-cycling proteins, and
protein kinases (such as PKCα and PKCε known to phos-
phorylate cardiac contractile proteins) are thyroid hormone
responsive [94, 97–100].
Loss of contracting myocardium due to MI results in a
chronic increase in the work load of the remaining viable
myocardium. The heart responds with an increase in muscle
mass, and this process of heart hypertrophy represents a
fundamental compensatory mechanism that permits the
ventricle to sustain normal perfusion pressure. In response
to this pressure overload left ventricular (LV) hypertrophy is
the primary remodeling process in the myocardium. There
is strong evidence implicating the role of ROS signaling in
the genesis of cardiac hypertrophy. Complex and interesting
interactions occur between cardiac hypertrophy induced
by excess thyroid hormone action and cardiac hypertro-
phy occurring with heart failure. The thyroid hormone-
mediated cardiac hypertrophy in its initial phases presents
a physiological hypertrophy with increases in SERCA2 levels
and decreased expression of β-MHC. In contrast, pressure
overload-induced heart failure leads to a “pathological” car-
diac hypertrophy which is largely mediated by the activation
of the calcineurin system and the MAP kinase-signaling
system responsive [94, 97–100].
Although the biological mechanisms for progression and
ventricularremodeling havenodeﬁnite explanation, mount-
ingevidencesupportsthetheorythatventriculardysfunction
worsens due to myocyte apoptosis as a consequence of
increased ROS formation [101]. It has been demonstrated
that a new signaling molecule, p66shc, which links oxidative
stress and apoptosis is upregulated in HF. p66shc is an
oxidant stress-induced, proapoptotic protooncogene known
to be activated by phosphorylation in response to stimuli
such as H2O2, UV radiation, or epidermal growth factor.
Transgenic disruption of p66shc or inactivation of its
ability to be phosphorylated confers resistance to oxidative
damage and prolongs life in mice [102]. Ask1, a 160kDa
serine/threonine protein kinase, is an ROS-sensitive MAP
kinase and is responsible for activation of both p38 and
Jnk pathways [103]. Ask1 is ubiquitously expressed in
most mammalian cells is activated by many stress signals
like ROS and proinﬂammatory cytokines including TNF-
α. G-protein-coupled receptors agonist e.g. nor-epinephrine,
angiotensin II, and endothelin also activate Ask1 via ROS
generation. Ask1 is also involved in NF-κB activation and
cardiomyocyte hypertrophy via G protein-coupled receptor
[13]. Overexpression of Ask1 induces apoptosis in car-
diomyocytes. It has been observed that signaling pathways
link myocardial apoptosis with cellular ability to cope with
oxidative stress.
Increase in apoptotic rates and DNA laddering was de-
tectable in T4-treated rat hearts. Angiotensin II further
increased the apoptotic rate of hyperthyroid hypertrophied
cardiomyocytes. The apoptotic rate in cardiomyocytes was
dependent on the extent of cardiomyocyte hypertrophy and
also susceptibility to apoptotic stimulation by angiotensin
II. Depressed cardiac contractility and enhanced apoptosis
may lead to heart failure in hypertrophied hyperthyroid
myocardium [104]. Very few evidences regarding the pro-
gression of apoptosis in hypothyroid heart is present which
open the door for further investigation in this ﬁeld.
6.2.Cardiomyopathy. Cardiomyopathy,whichliterallymeans
“heart muscle disease,” is the deterioration of the function
of the myocardium leading to risk of arrhythmia or sudden
cardiac death or both. Cardiomyopathies are now deﬁned as
diseases of the myocardium associated with cardiac dysfunc-
tion and classiﬁed by the dominant pathophysiologic fac-
tors. These include dilated cardiomyopathy (dilation of left
ventricle), hypertrophic cardiomyopathy (abnormal thick-
ening of heart muscle), restrictive cardiomyopathy (heart
muscle becomes rigid and less elastic), arrhythmogenic right
ventricular cardiomyopathy, and speciﬁc cardiomyopathy.
The term “speciﬁc cardiomyopathy” is now used to describe
heart muscle diseases that are associated with speciﬁc cardiac
or system disorders. The condition may also be caused by
diseases elsewhere in the body that aﬀect the heart, such as
amyloidosis, a rare condition in which abnormal proteins
present in the blood are deposited into the heart.
It has been determined that there is increase in oxidative
stress in patients with dilated cardiomyopathy by proving
that erythrocytes and erythrocyte membranes from these
patients were more prone to LPX and oxidative damage
than those from healthy controls. These results show that
antioxidant defense of erythrocytes in patients with dilated
cardiomyopathy is weak compared with that in healthy con-
trols. Patients with dilated cardiomyopathy have impaired
myocardial contractility and can have fatal ventricular
arrhythmias. Membrane changes due to increased oxidative
stress may be partly responsible for these manifestations of
the disease although ROS cannot be totally responsible for
the particular disease. Although peroxidation of membrane
lipids is a relatively slow process, however, it increases LPX
due to recurring ischemia-reperfusion cycles in the heart and
skeletal muscle, catecholamine autoxidation, and changes in
membrane proteins. In this respect,i nv i t r ostudies have
shown that oxidative stress induces oxidation of SH groups
and can impair Ca2+-ATPase activity of sarcoplasmic reticu-
lum [105], and Na+ K+-ATPase of plasma membranes [106].
Moreover, alterations of hormone receptors containing a
critical SH moiety, involved in maintaining calcium home-
ostasis, results in intracellular calcium overload and hence8 The Scientiﬁc World Journal
contribute to the mechanism of contractile dysfunction and
ventricular arrhythmias in dilated cardiomyopathy. Release
of these ROS due to conversion of xanthine dehydrogenase
to xanthine oxidase during purine degradation may perox-
idize the cell membrane [107]. It has been demonstrated
that myocardial high-energy phosphate concentrations were
reduced in patients with dilated cardiomyopathy [108].
Activity of creatine kinase (EC 2.7.3.2), which plays an
important role in rapid resynthesis of ATP when the heart
increases its work in myocardial and skeletal muscle in case
of high-energy phosphate metabolism, is also impaired as a
result of ROS-induced SH group oxidation at the active site
(Figure 2). It has been found that inhibition of the reac-
tion of creatine kinase decreases the contractile reserve
of the isolated rat heart-dilated cardiomyopathy [109].
Nevertheless, a relative deﬁcit in antioxidant reserves may
contribute to cardiac failure [110]. Therefore, exogenous
administration of antioxidants may slow the progression
of cardiac abnormalities and may decrease the incidence
of life-threatening ventricular arrhythmias or sudden death
in dilated cardiomyopathy or, generally, in congestive heart
failure.
Reversible cardiomyopathy has been associated with en-
docrine dysfunction including thyroid dysfunction although
extensive work in this regard has not been carried out. Excess
thyroid hormones can lead to cardiac disease through the
potential mechanism of thyrotoxicosis which is associated
with high cardiac output failure. Hyperthyroidism results in
tachycardia and atrial ﬁbrillation which have been reported
as causes of cardiomyopathy (Figure 1)[ 111].
6.3. Myocarditis. Cardiomyopathy can sometimes develop
after exposure to a virus. Viral myocarditis is usually a self-
limited disease but may occasionally lead to severe cardiac
damage and heart failure. Cardiac damage in coxsackievirus
myocarditis involves not only apoptotic but also necrotic
cardiomyocyte death [112–117]. Increase in apoptosis and
reduction in plasma GSH levels in cardiomyocytes of AVM
patients suggests the role of ROS in the induction of car-
diomyocyte apoptosis during CVB3 myocarditis. It has been
reported that GPx knockout mice with reduced antioxidant
capabilities develop more severe myocarditis when infected
with CVB3 as compared to wild-type mice [118]. Serious
pathological aggravation of oxidative stress and severe
disturbance of nitric oxide metabolism has been found in
patients suﬀering from acute viral myocarditis (AVM). The
inﬂammatory cytokines particularly interleukin-I (IL-1) are
released by phagocytic cells like lymphocytes, neutrophils,
granulocytes,andmacrophagesintheinﬂammatoryreaction
in the cardiac muscle cells and tissues as a result of oxidative
stress. This in turn activates iNOS which releases large
amount of NO which combines with superoxide anion
radical to produce ONOO−, damaging cell functions and
deactivating the antioxidases such as superoxide dismutase,
catalase, and glutathione peroxidase, by combining with
their hydrosulﬁde group (-SH) [119, 120]. Moreover, exces-
sive nitric oxide is rapidly oxidized into nitrogen dioxide,
which acts as catalyst in the LPx of polyunsaturated fatty
acids, thus peroxidizing the cell and tissue membranes. In
addition to this, the signiﬁcant decrease in the synthesis or
regeneration of glutathione peroxidase resulting in loss of
GPxactivityofremovinglipoperoxide.Allthesemechanisms
might be responsible for the signiﬁcant increase in the level
of lipoperoxide in the AVM patients’ bodies [119–122].
Additionally, the AVM patients appear to have poor appetite
because of their temperature elevation resulting in reduced
intake of dietary antioxidants (such as vitamin C, vitamin
E, and β-carotene). This leads to a signiﬁcant decrease in
the antioxidants levels in their bodies which disrupts the
dynamic imbalance between oxidation and antioxidation,
resultinginpathologicalaggravationofaseriesoffreeradical
chain reactions in the patients’ bodies.
Graves’ disease and/or hyperthyroidism has been found
to be associated with myocarditis. Evidence suggests that
there is an association between lymphocytic myocarditis and
lmphocytic thyroiditis. On the other hand, hypothyroidism
and Hashimoto’s thyroiditis have never been reported in
association with myocarditis as a cause of sudden death
[123–127]. The reason why myocarditis has been found
exclusivelyinhyperthyroidismandGraves’diseaseandnotin
hypothyroidism and Hashimoto’s thyroiditis is still a matter
of debate. One explanation may be that the symptoms of
myocarditis may be due to autoimmune myocarditis rather
than a viral infection.
6.4. Valvular Disease. Heart valve problems can result from
disease, infection (endocarditis), or a defect present at birth.
When the valves do not open or close completely during
each heartbeat, the heart muscle has to pump harder to keep
the blood moving. Heart failure results when the workload
becomes too great. Heart valves are composed mainly of
extracellular matrix, smooth muscle cells, ﬁbroblasts, and
endothelial cells [128].
“Degenerative” aortic valve stenosis (AVS) is a valve dis-
ease. It increases with advancing age in comparison with
rheumatic diseases, which prevail in younger populations.
Degenerative and rheumatic HVD is caused by several risk
factors such as genetic, inﬂammatory, autoimmune, infec-
tious,andoxidativestress[129].Calciﬁedaorticvalvedisease
ranges from mild aortic valve sclerosis to severe aortic
valve stenosis. It is a regulated disease process and shares
pathophysiologicalfeatureswithatherosclerosis.Histological
analysis of valve lesions showed similarities to atherosclerotic
plaque evolution, such as the presence of lipoproteins, foam
cells, macrophages, T lymphocytes, extracellular matrix
proteins,heterotopiccalciﬁcation,andbonetissue.Thesetis-
sue factors may be the result of “active” biologic processes
of chronic inﬂammation and tissue repair, sustained by
angiogenesis similar to the processes involved in atheroscle-
rosis. Fibrosis and calciﬁcation are characteristic features
of degenerative aortic valve lesions [130]. The calciﬁed
aortic valve lesion develops endothelial injury and is char-
acterized by chronic inﬂammation [131], lipoprotein accu-
mulation [132], renin-angiotensin system activation [133],
and ﬁbrosis. Coronary atherosclerosis and valvular sclerosis
are similar processes, and they may occur coincidentally
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atherosclerotic lesions and contain calcium, oxidized low-
density lipoproteins, areas of neovascularization, high levels
of matrix-remodeling enzymes, and apoptotic cells within
the valvular plaque. Oxidative modiﬁcation of low-density
lipoprotein by ROS has been reported to inﬂuence initiation
and progression of valve lesions [132]. The role of oxidative
stress and systemic inﬂammation in rheumatic HVD is
well established [130]. In contrast to atherosclerotic lesions,
increased oxidative stress seems to be partly due to reduc-
tions in antioxidant enzyme expression and activity [130]. In
addition, NOS uncoupling might play an important role in
the generation of superoxide in calciﬁed aortic valves leading
to the pathophysiology of degenerative AVS (Figure 2).
The possible linkage of thyroid dysfunction and valve
sclerosis has not been investigated so far although it may
be regarded as pathophysiologically plausible. However, a
possible association between thyroid dysfunction might at
least explain the elevated cardiovascular mortality reported
in thyroid dysfunction, taking into consideration that AVS
and MAC (mitral annular calciﬁcation) are markers of
increased cardiovascular mortality.
6.5. Hypertension. In high blood pressure (BP), the pressure
and resistance in the body’s arteries is increased. Uncon-
trolled high blood pressure increases the risk of developing
heart failure by two to three times. When pressure in the
blood vessels is too high, the heart has to pump harder
than normal to keep the blood circulating. This takes a toll
on the heart, and overtime the chambers get larger and
weaker. Oxidative stress may contribute to the generation
of hypertension by various mechanisms which includes
quenching of the vasodilator nitric oxide (NO) by ROS [135]
generation of vasoconstrictor lipid peroxidation products,
such as F2-isoprostanes [136] depletion of tetrahydrobio-
pterin (BH4), an important NO synthase (NOS) cofactor
[137]a sw e l la ss t r u c t u r a la n df u n c t i o n a la l t e r a t i o n sw i t h i n
the vasculature [138]. Oxidative stress promotes vascular
smooth muscle cell proliferation and hypertrophy and
collagen deposition, leading to thickening of the vascular
media and narrowing of the vascular lumen. In addition,
increased oxidative stress may damage the endothelium
and impair endothelium-dependent vascular relaxation and
increases vascular contractile activity. All these eﬀects on the
vasculature may explain how increased oxidative stress can
cause hypertension.
T h e r ea r ean u m b e ro fp o s s i b l es o u r c e so ff r e er a d i c a l
production within the vasculature which include NADPH
oxidase, NOS, cyclooxygenases, lipoxygenases, and xanthine
oxidase, all of which are functional in endothelial cells.
During the metabolism of arachidonic acid by CYP450,
an important cofactor is the NADPH oxidase system,
superoxide, hydrogen peroxide, and hydroxyl radicals are
generated. Cytochrome 450 2C9 isoform is a functionally
signiﬁcant source of ROS in coronary arteries has shown
by in vitro studies (Figure 2). These studies indicate that
CYP450 plays an important role in endothelial dysfunction
and hypertension by production of oxidative stress within
the vessel wall [139]. One important endogenous regulator
of CYP450 metabolism is thyroid hormone, T3, which not
only contributes to the regulation of certain hepatic CYP450
enzymes but is also a key determinant of the expression of
CYP450R in other tissues.
Human studies have not been as consistent as animal
studiesandresultsvarydependingonthemarkerofoxidative
damage being investigated. Studies using nonspeciﬁc mark-
ers of oxidative damage have observed higher superoxide
and hydrogen peroxide production in individuals suﬀering
from hypertension, which returned to basal levels following
reduction in BP [140]. Reductions in SOD and glutathione
peroxidase activity have been observed in hypertensives with
no history of early treatment when compared with controls
which shows that SOD activity was inversely correlated with
reductionBPwithinthehypertensivegroup,butnotcontrols
[141]. There is a signiﬁcant correlation between hydrogen
peroxidelevels,andsystolicBPashigherproductionofH2O2
has also been observed in treated and untreated hyperten-
sives compared with normotensives [142]. An imbalance
in superoxide and nitric oxide production may account
for reduced vasodilation, which in turn can favor the
development of hypertension. In vitro and in human studies
support this hypothesis (Figure 2).
Regarding hypertension, endothelial cells play a major
role in arterial relaxation by releasing NO in the vasculature.
Nitric oxide causes vascular relaxation [143]. Nitric oxide
synthase (NOS), and in particular the endothelial isoform of
NOS (eNOS), is now recognized as an important source of
O2
·− which is a major determinant of NO biosynthesis and
bioavailability [144, 145]. It has been found that eNOS can
generatesuperoxideinsteadofNOinresponsetoatherogenic
stimuli. This led to the concept of “NOS uncoupling,”
where the activity of the enzyme for NO production is
decreased,inassociationwithanincreaseinNOS-dependent
superoxide production [146] leading to a dramatic increase
in peroxynitrite formed by the NO-superoxide reaction.
This has additional harmful eﬀects on vascular function by
oxidation of cellular proteins and lipids [147].
Recently it has been reported that vascular endothelium
is a target of TH and an excessive endothelial NO production
plays a role in vasodilation in hyperthyroidism. In addition,
increased vascular NO production has been reported in rats
inhyperthyroidstatesoraftertreatmentwithT3 [148].Nitric
oxide (NO) production by VSMCs has been considered as
one of the causes of overproduction of NO in the vascular
wall and might be responsible for the local control of
vascular function [149] .Ap r e v i o u ss t u d yd e m o n s t r a t e dt h a t
hyperthyroidism reduces both vasoconstriction and blood
pressure elevation induced by catecholamines, which also
involves NO generation [150]. Thyroid hormone acutely
stimulates relaxation of VSMCs by increasing production
of NO which occurs rapidly by the activation of iNOS and
nNOS via mechanism of the PI3K/Akt-signalling pathway
[151–153].
Increasing number of evidences indicates that NADPH-
driven generation of ROS and activation of reduction-
oxidation (redox)-dependent signaling cascades are involved
in the role of Angiotensin II-induced hypertension [154]
documented in cardiomyocytes, vascular and endothelial
cells. There is an increase in Ang II-dependent ﬁltration of10 The Scientiﬁc World Journal
circulating neutrophils into myocardial tissues and which
may be a source of ROS by increasing expression of inﬂam-
matory cytokines. Ang II elicits its actions via two distinct
receptors: the Ang I receptors (AT1R) and Ang II receptors
(AT2R) which are ideal candidates for maintaining a proper
balancebetweenNOandROS[154,155].Ithasbeendemon-
stratethatAngII,actingthroughtheAT1receptor,stimulates
nonphagocytic NADPH oxidase, causing the accumulation
of superoxide, hydrogen peroxide, and peroxynitrite produce
an inﬂammatory response in pathophysiological conditions
(Figure 2). Blockage of AT1R will stimulate the AT2R and
oppose the eﬀect of AT1R activation, a mechanism that
appears to be involved in the beneﬁcial eﬀects of the
angiotensin receptor blockers. Collectively, these results
indicatethatchroniclossofangiotension-convertingenzyme
(ACE2) leads to AT1R -mediated NADPH oxidase acti-
vation, increased oxidative stress, neutrophil recruitment,
and MAPK activation through GCPR-signalling ultimately
leading to adverse ventricular remodeling and heart disease
[156].
Thyroid hormone downregulates AT1R mRNA expres-
sion at both transcriptional and posttranscriptional levels.
Evidences showed that vascular endothelium is a target
of thyroid hormone, and an excessive endothelial NO
production plays a role in vasodilation in hyperthyroidism
[157]. It has been reported that NO donor inhibited AT1R
expression in VSMCs [158]. Therefore, it may be possible
that T3 indirectly inhibits vascular AT1R expression through
the production of NO in addition to direct downregulation
of AT1R. Thyroid hormone increases the basal metabolic
rate in almost every tissue and organ in the body, and
increased metabolic demands lead to changes in cardiac
output, (systemic vascular resistance) SVR and BP. Hyper-
thyroidismhasbeenreportedasasecondarycauseofisolated
systolic hypertension, which is the most common cause
of hypertension, and can be reverted back to normal by
treatment of hyperthyroidism and use of β-blockade. Hyper-
thyroidism also causes diastolic hypertension by causing
endothelial dysfunction, impaired VSM relaxation which
leads to increased SVR and can also be reverted back by
thyroid hormone replacement. Thyroid hormone causes
resistanceinperipheralvasculaturethroughadirecteﬀecton
VSM and decreased mean arteriole pressure, and this change
is sensed by the juxtaglomerular apparatus of kidneys which
is volume and pressure sensitive. This leads to the activation
of the rennin-angiotension system and increase in rennin
secretion. This is followed by a cascade of events including
increasedlevelsofangiotensinIandII,angiotensionconvert-
ing enzyme (ACE) and aldosterone while increasing blood
volume and preload and thus contributes to characteristic
increase in cardiac output and BP [159]. In hyperthyroidism
the combined eﬀects of decreased SVR, increased heart rate,
and blood volume eﬀects increase cardiac output 50–300%
higher than in normal individuals. On the other hand in
hypothyroidism it is just opposite and cardiac output may
decrease by 30–50% [160]. Hypothyroidism is accompanied
by a rise in diastolic BP because of low cardiac output
and narrow pulse pressure. There are various evidences
suggesting the role of natriuretic peptides in regulation of
salt and water balance and thus in regulation of BP. Thyroid
hormone aﬀects the expression of the prohormone genes
for each natriuretic peptide which is altered with changes in
thyroid disease state [161].
6.6. Congenital Heart Disease. In the heart and its chambers
if incorrectly formed, the healthy parts have to work harder
to make up for it. Oxygen-free radicals are incriminated
in the causation of several congenital diseases. Oxidative
stress, due to ROS and RNS, may contribute to phenotypic
changes in infants hearts adapted to chronic hypoxia and
to the pathogenesis of myocardial injury during both
ischemia/reperfusion and hypoxia/reoxygenation (Figure 2).
Cardiovascular disease is a signiﬁcant cause of death and
chronic illness in childhood. There is scarce data in literature
regarding the association between congenital heart disease
and oxidative stress in children. Children with congenital
heart disease have poorer clinical outcomes because hypoxia
in these children reduces the antioxidant reserve capacity
leading to a greater susceptibility to the oxidative stress
[162]. The potential contribution of oxidative stress to
cardioprotection in infants induced by adaptation to chronic
hypoxia and by ischemic preconditioning is poorly under-
stood. Endothelial nitric oxide synthase (eNOS) protein and
its product nitric oxide are increased in chronically hypoxic
infant hearts to protect against ischemia. Thus, eNOS
appears to be critically important in adaptation of infant
hearts to chronic hypoxia and in resistance to subsequent
ischemia by regulating the production of reactive oxygen
species [163]. Infants and children also suﬀer from some
important thyroid hormone-related heart disease which in
most cases is a side eﬀect of thyroid disorder in the mother.
Maternal illnesses play a signiﬁcant role in the development
of heart defects in fetuses. Although the embryo does not
have the disease, prolonged exposure to metabolites of the
maternal illness leads to the development of congenital
malformations. In case of hyperthyroid mothers, thyroid-
stimulating immunoglobulin can cross the placental barrier
and stimulate the fetal thyroid gland, causing neonatal
hyperthyroidism leading to conditions like tachycardia,
bounding pulses, systolic hypertension, a systolic murmur,
and sometimes congestive heart failure, in infants. If treat-
ment for neonatal hyperthyroidism is delayed or inade-
quate, potentially fatal arrhythmias and cardiac failure may
develop. Exposure to iodine might occur during cardiac
catheterisation or surgery and may induce a transient form
of hypothyroidism in infants [164]. Evidences indicate that
t h eh e a r td r u ga m i o d a r o n e ,w h i c hi sa ne x t r e m e l ye ﬀective
treatment for infants and children with tachyarrhythmias
may also cause hypothyroidism as a side eﬀect [165].
6.7. Epilogue. Oxidative stress is one of the causes of heart
failure, and many of the therapies proven to be of clinical
beneﬁt targets at reducing this stress in vivo. Drugs that are
established to improve the excessive oxidative stress may act
indirectly for treatment in heart failure. Treatment with β-
adrenoceptor blockers like carvedilol and nebivolol reduces
generation of ROS by the activation of Jun kinases and
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properties [166, 167]. Statins treatment has irrespective of
theircholesterol-loweringactivity,leadstoreducedGprotein
signalling response [168]. ACE inhibitors and angiotensin
receptorblockershavebeenshowntoreduceBPandmarkers
of oxidative stress in target tissues by reducing the G protein
linkedsignalingtoNAD(P)Hoxidase.Anotherdrugrosuvas-
tatin also reduces the rate of heart failure signiﬁcantly [169].
Hydralazine has been demonstrated to reduce mortality in
heart failure [170] and has additional inhibitory eﬀects on
the generation of superoxide and peroxynitrite [171]. Two
other trial drugs, like allopurinol and its active metabolite
oxypurinol[172],havebeentestedextensivelyinheartfailure
cases. Other drugs with antioxidant properties, such as
probucol [173], edaravone [174] have been used in the treat-
mentofoxidativestress-relateddiseases.Irbesartandecreases
inﬂammation which contributes to plaque stabilization
by inhibition of MMPase-induced plaque rupture [175].
Mevalonate is a precursor for the synthesis of ubiquinone,
a natural antioxidant essential for mitochondrial electron
chain transport activity, and essential heart function. The
use of combination supplement of zinc, ascorbic acid, a-
tocopherol, and β-carotene has been tested in reduction of
systolic and diastolic blood pressure [176]. However, large
clinical trials of the antioxidant vitamins (A and E) or their
precursors have been disappointing, with no evidence of
beneﬁt on cardiac mortality or morbidity.
The discussions vide supra advocates the role of thy-
roid dysfunctions in the pathophysiology of heart diseases
mediated by ROS. In a preliminary study reported that the
level of LPX increased in the cardiac mitochondria of PTU-
treated hypothyroid rats which returned to normal upon T3
treatment. On the other hand, mitochondrial SOD activity
reduced under hypothyroid condition which was further
reduced upon T3 supplementation. In contrast, altered thy-
roid status failed to elicit any change in mitochondrial SOD
activity. In case of postmitochondrial fraction, hypothyroid
state did not alter the SOD activity, but T3 supplementation
augmented the enzyme activity. The increased catalase
activity observed in postmitochondrial fraction of rat heart
came to the level of control upon T3 supplementation. The
results thus surmise that any alteration in thyroid status may
cause subtle changes in cardiac tissue leading to oxidative
tissue injury and thyroid hormone replacement therapy is
inadequate in bringing back the tissue parameters to normal
levels [177]. Albeit antioxidant therapy is not the direct
answer to thyroid induced cardiac dysfunction, it promises
to minimize tissue damage and accompanying symptoms in
this hormonal disorder.
Altered-thyroid-state-linked changes in the tissues like
heart modify their susceptibility to oxidants and the extent
of the oxidative damage they suﬀer following oxidative
challenge.Identiﬁcation of speciﬁc TH-responsive molecular
pathways via ROS will provide further information related
to molecular mechanisms by which changes in the thyroid
status alter heart function. However, unrevealing the molec-
ular pathways by which ROS inﬂuences cardiac functions
is intimidating because of the involvement of multiple
signaling pathways and cell targets (Figure 3). Nevertheless
understanding few of these pathways may at least provide
Oxidative stress
Hypothyroidism
Lipid peroxidation ↓
SERCA ↓, PLB ↑,C a 2+ ↓
NADPH oxidase ↑
LDL oxidation ↑
NFκB activation?
Mitochondrial leakage ↑ Mitochondrial leakage ↑
NOS ↓
Hyperthyroidism
Lipid peroxidation ↑
LDL oxidation ↑
NADPH oxidase ↑
SERCA ↑, PLB ↓,C a 2+ ↑
NFκB activation ↑
NOS ↓
Figure 3: Cardiac oxidative stress under altered thyroid states.
a plausible road-map of further investigation using animal
models to establish a casual link between altered thyroid
states induced oxidative stress and heart failure. Futuristic
approaches such as antioxidant treatment and gene therapy
using viral vectors to modulate the expression of antioxidant
genes appear to be a promising strategy to counter oxidative
stress-induced myocardial damage.
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